ArticleOral diseases2026
Radiographic Analysis of MRONJ in Osteoporotic and Oncologic Patients on Bisphosphonates or Denosumab.
Article in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Uncovering jaw-specific radiographic differences in medication related osteonecrosis of the jaws (MRONJ): a case-control study.Clinical oral investigations · 2026Article
- Radiographic Patterns and Clinical Correlates of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Retrospective Analysis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMedication-Related Osteonecrosis of the Jaw (MRONJ) is a severe adverse effect of antiresorptive and antiangiogenic treatment, primarily in osteoporotic and oncologic patients. The disease is characterized by persistent jawbone necrosis that results in significant impairment of the quality of life of involved patients. The aim of this study is to compare the radiographic characteristics of MRONJ between osteoporotic and oncologic patients and assess the differences based on treatment type, particularly bisphosphonates and denosumab (RANK-L inhibitors).
methodsA retrospective analysis of 152 MRONJ patients (41 osteoporotic, 111 oncologic) from Rabin-Bilinson Medical Center (2014-2024) examined radiographic features-lytic changes, sclerosis, periosteal reactions, sequestration, and periodontal ligament destruction-using panoramic radiography, CBCT, and MDCT.
resultsSclerosis was more frequent in osteoporotic patients compared to oncologic patients (p < 0.05). No statistically significant differences were found in other radiographic features. Bisphosphonate-induced MRONJ was more frequently accompanied by sclerosis compared to denosumab-related cases in osteoporotic patients (p = 0.0318), while no significant differences were found in the oncologic group.
conclusionsMost of the radiographic features of MRONJ were similar in osteoporotic and oncologic patients. However, sclerosis was more common in osteoporotic patients exposed to Bisphosphonates, which may be due to their prolonged exposure to antiresorptive drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.